Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680790 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites reduced: 208 → 201 locations · Start date changed from estimate of Sep 30, 2026 to Sep 8, 2026 · Eligibility criteria expanded, about 8 words Show 3 more changesShow less
    • Trial sites reduced: 208 → 201 locations
    • Start date changed from estimate of Sep 30, 2026 to Sep 8, 2026
    • Eligibility criteria expanded, about 8 words
  2. Trial sites expanded: 200 → 208 locationsv3
  3. Trial sites expanded: 180 → 200 locationsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Trial Details
NCT Number NCT07680790
Lead Sponsor Bristol-Myers Squibb
Conditions Non-Small Cell Lung Cancer
Enrollment 850 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov